Page 228 - 2021_09-Haematologica-web
P. 228
Letters to the Editor
Synergistic interaction between HDAC and MCL-1 inhibitors through downregulation of BCL-XL in multiple myeloma
The development of novel therapies is the most important catalyst for the advancement in the treatment of patients with multiple myeloma (MM). Presently, a
number of new therapies including immunotherapeutic drugs, cellular therapies and BH3 mimetics are intro- duced into clinical practice. This steadily increasing number of effective treatment options makes it practi- cally impossible to compare all available regimens and treatment concepts with each other in different settings. Hence, it becomes increasingly important to obtain a
ABC
DEF
GHI
JKL
MN
Figure 1. Legend on following page.
2516
haematologica | 2021; 106(9)
